Menu
Search
|

Menu

Close
X

Redhill Biopharma Ltd RDHL.OQ (NASDAQ Stock Exchange Capital Market)

6.28 USD
+0.06 (+0.96%)
As of Feb 23
chart
Previous Close 6.22
Open 6.37
Volume 4,996
3m Avg Volume 44,483
Today’s High 6.37
Today’s Low 6.05
52 Week High 11.24
52 Week Low 4.30
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Dror Ben-Asher
Chairman of the Board, Chief Executive Officer, Since 2011
Salary: $262,454.00
Bonus: --
Micha Ben Chorin
Chief Financial Officer, Since 2016
Salary: $162,642.00
Bonus: --
Gilead Raday
Chief Operating Officer, Since 2016
Salary: $218,087.00
Bonus: $40,000.00
Reza Fathi
Senior Vice President - Research & Development, Since 2010
Salary: $246,000.00
Bonus: --
Adi Frish
Senior Vice President - Business Development and Licensing, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Platinum building, 21 Ha'arba'a
TEL AVIV-YAFO     6473921

Phone: +9723.5413131

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

SPONSORED STORIES